Literature DB >> 22619040

Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.

Mary E Platek1, Susan A McCloskey, Myra Cruz, Mark S Burke, Mary E Reid, Gregory E Wilding, Nestor R Rigual, Saurin R Popat, Thom R Loree, Vishal Gupta, Graham W Warren, Maureen Sullivan, Wesley L Hicks, Anurag K Singh.   

Abstract

BACKGROUND: The purpose of this study was to quantify the effect of treatment duration on locoregional progression after definitive concurrent chemoradiation (CCRT) for squamous cell carcinoma of the head and neck (SCCHN).
METHODS: We conducted a retrospective chart review of patients treated between 2004 and 2010. After a prior analysis, measures were taken to limit therapy beyond 7 weeks. Comparison of outcomes were made between cohorts 1 (2004-2007, n = 78) and 2 (2007-2010, n = 62).
RESULTS: Median therapy duration was statistically significantly different between cohorts as follows: 51 days, cohort 1 and 46 days, cohort 2 (p < .01). Locoregional progression in cohorts 1 and 2 was 19% and 5% (p = .01), respectively. On multivariate analysis, patients with prolonged treatment (≥57 days) had an 8-fold increase in risk of locoregional progression compared to patients who completed on time (p < .01).
CONCLUSION: Treatment duration was a significant predictor of locoregional progression in patients with SCCHN who received definitive CCRT.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22619040      PMCID: PMC5061340          DOI: 10.1002/hed.23024

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  27 in total

1.  Accelerated repopulation in head and neck cancer.

Authors:  H R Withers; B Maciejewski; J M Taylor; A Hliniak
Journal:  Front Radiat Ther Oncol       Date:  1988

2.  Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers.

Authors:  C Robertson; A G Robertson; J H Hendry; S A Roberts; N J Slevin; W B Duncan; R H MacDougall; G R Kerr; B O'Sullivan; T J Keane
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-15       Impact factor: 7.038

3.  The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma.

Authors:  D L Kwong; J S Sham; D T Chua; D T Choy; G K Au; P M Wu
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

4.  Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.

Authors:  Rafal Suwinski; Anna Sowa; Tomasz Rutkowski; Jerzy Wydmanski; Rafal Tarnawski; Boguslaw Maciejewski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

Review 5.  Applying radiobiological principles to combined modality treatment of head and neck cancer--the time factor.

Authors:  L J Peters; H R Withers
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-11-01       Impact factor: 7.038

6.  Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.

Authors:  B Maciejewski; H R Withers; J M Taylor; A Hliniak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

7.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

Review 8.  Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes.

Authors:  David I Rosenthal
Journal:  J Support Oncol       Date:  2007-10

9.  The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.

Authors:  N J Slevin; J H Hendry; S A Roberts; A Agren-Cronqvist
Journal:  Radiother Oncol       Date:  1992-08       Impact factor: 6.280

10.  The hazard of accelerated tumor clonogen repopulation during radiotherapy.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

View more
  23 in total

1.  The effect of time between diagnosis and initiation of treatment on outcomes in patients with head and neck squamous cell carcinoma.

Authors:  Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh
Journal:  Oral Oncol       Date:  2019-07-30       Impact factor: 5.337

2.  Two- Versus Four-Times Weekly Acupuncture-Like Transcutaneous Electrical Nerve Stimulation for Treatment of Radiation-Induced Xerostomia: A Pilot Study.

Authors:  Austin J Iovoli; Alexander Ostrowski; Charlotte I Rivers; Gregory M Hermann; Adrienne Groman; Austin Miller; Anurag K Singh
Journal:  J Altern Complement Med       Date:  2020-01-27       Impact factor: 2.579

3.  Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck.

Authors:  Michael Mix; Anurag K Singh; Michael Tills; Shiva Dibaj; Adrienne Groman; Wainwright Jaggernauth; Youcef Rustum; Michael B Jameson
Journal:  World J Clin Oncol       Date:  2015-10-10

4.  Mortality following single-fraction stereotactic body radiation therapy for central pulmonary oligometastasis.

Authors:  Sung Jun Ma; Michael Mix; Charlotte Rivers; Mark Hennon; Jorge Gomez; Anurag K Singh
Journal:  J Radiosurg SBRT       Date:  2017

5.  The impact of dietary regimen compliance on outcomes for HNSCC patients treated with radiation therapy.

Authors:  Rafi Kabarriti; Amanda Bontempo; Maria Romano; Kevin P McGovern; Alyssa Asaro; Shankar Viswanathan; Shalom Kalnicki; Madhur K Garg
Journal:  Support Care Cancer       Date:  2018-04-18       Impact factor: 3.603

6.  Pretreatment weight status and weight loss among head and neck cancer patients receiving definitive concurrent chemoradiation therapy: implications for nutrition integrated treatment pathways.

Authors:  Mary E Platek; Elizabeth Myrick; Susan A McCloskey; Vishal Gupta; Mary E Reid; Gregory E Wilding; David Cohan; Hassan Arshad; Nestor R Rigual; Wesley L Hicks; Maureen Sullivan; Graham W Warren; Anurag K Singh
Journal:  Support Care Cancer       Date:  2013-06-07       Impact factor: 3.603

7.  Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.

Authors:  Ilia A Toshkov; Anatoli S Gleiberman; Vadim L Mett; Alan D Hutson; Anurag K Singh; Andrei V Gudkov; Lyudmila G Burdelya
Journal:  Radiat Res       Date:  2017-03-21       Impact factor: 2.841

8.  Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.

Authors:  Yih-Lin Chung; Newman N M Pui
Journal:  Support Care Cancer       Date:  2017-03-28       Impact factor: 3.603

9.  Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation.

Authors:  Alexis J Platek; Vijayvel Jayaprakash; Mihai Merzianu; Mary E Platek; David M Cohan; Wesley L Hicks; Sathiya P Marimuthu; Timothy B Winslow; Vishal Gupta; Hassan Arshad; Moni A Kuriakose; Shiva Dibaj; James R Marshall; Mary E Reid; Graham W Warren; Anurag K Singh
Journal:  Laryngoscope       Date:  2016-06-27       Impact factor: 3.325

10.  Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.

Authors:  Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Elizabeth A Repasky; Anurag K Singh
Journal:  Oral Oncol       Date:  2020-06-16       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.